+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North American Neurological Disorder Drugs Market 2020-2026

  • PDF Icon


  • April 2020
  • Region: North America
  • Orion Market Research Private Limited
  • ID: 5241105
North American Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026.

The North American neurological disorder drugs market is projected to grow at a significant CAGR during the forecast period (2020-2026). The key factors that drive the growth of the market include the rising prevalence of neurological disorders among people across the globe. The rising geriatric population is another major reason for market growth in the North American region. As per the US Census Bureau, in 2010, there were more than 40.3 million US residents of 65 years and older whereas, the count raised to more than 54 million in July 2019. Elder people are more prone to diseases and such neurological disorders, thus creating a wide scope for the North American neurological disorder drugs market. Besides, the launch and innovations of novel products by the key players further supports the growth of the market.

The North American neurological disorder drugs market is segmented on the basis of disorder type into Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington disease, and others. Amongst the disorder type segment, Parkinson’s disease segment is projected to hold a lucrative share in the market. The segmental growth of the market is attributed to the increased prevalence of Parkinson’s disease among people across the globe. A broad range of drugs is used for the treatment of neurological disorders, some of which include analgesics, antihypertensive, anticholinergic, hypnotic & sedatives, and others.

Geographically, the North American neurological disorder drugs market is analyzed into the US and Canada. The US is estimated to dominate the market and will continue its dominance during the forecast period. Further, Eli Lilly and Co., Merck & Co. Inc., Allergan Plc., AstraZeneca Plc, Pfizer Inc., Biogen Inc., and Amgen Inc. are some of the players operating in the North American neurological disorder drugs market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players to sustain in the highly competitive market.

Research Methodology

The market study of the North America neurological disorder drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for the pharmaceutical industry, drug manufacturers, hospitals & clinics, research organizations, academic institutes, non-profit organizations, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. North America Neurological Disorder Drugs Market Research and Analysis by Disorder Type
2. The Report covers:
  • Comprehensive research methodology of the North American Neurological Disorder Drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the North American Neurological Disorder Drugs market.
  • Insights about market determinants which are stimulating the North American Neurological Disorder Drugs market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of the market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Major Drug Analysis
  • Analgesics
  • Antidepressants
  • Sedatives & Hypnotics
  • Antihypertensive
  • Others
2.3. Analyst Insight & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendations
2.3.3. Conclusion
2.4. Rules & Regulations
3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities
4. Market Segmentation
4.1. North America Neurological Disorder Drugs Market by Disorder Type
4.1.1. Alzheimer’s Disease
4.1.2. Parkinson’s Disease
4.1.3. Multiple Sclerosis
4.1.4. HuntingtonDisease
4.1.5. Others
5. Regional Analysis
5.1. US
5.2. Canada
6. Company Profiles
6.1. AbbVie Inc.
6.1.1. Overview
6.1.2. Abbvie Inc. in North America
6.1.3. Abbvies Inc. in Neurological Disorder Drugs Landscape
6.1.4. Recent Developments
6.2. ACADIA Pharmaceuticals Inc.
6.3. ApotexInc.
6.4. Allergan Plc
6.5. Amgen Inc.
6.6. AstraZeneca Plc
6.7. Biogen Inc.
6.8. Boehringer Ingelheim International GmbH
6.9. Eli Lilly and Co.
6.10. F. Hoffmann-La Roche Ltd.
6.11. Merck & Co. Inc.
6.12. Novartis AG
6.13. Pfizer Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • ACADIA Pharmaceuticals Inc.
  • ApotexInc.
  • Allergan Plc
  • Amgen Inc.
  • AstraZeneca Plc
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.